Items tagged with HIV coinfection
To meet HIV world health goals, TB treatment must be maintained during COVID-19 response (post)
New York, Dec. 1 2020 — The global COVID-19 pandemic has strained health care systems around the world. In the developing world, tuberculosis (TB), which shares several symptoms with COVID-19, is often the first sign that a person has HIV. This World AIDS Day, the Forum of International Respiratory Societies (FIRS), is calling on governments, health advocates and non-government organisations to strengthen their response to AIDS and tuberculosis, and to ensure that TB services are maintained throughout their response to COVID-19.
New test for diagnosis of tuberculosis meningitis in patients with HIV (post)
A new 60-minute point-of-care lateral flow assay featured the same sensitivity as mycobacterial culture in detecting tuberculosis meningitis (TBM) in adult patients with HIV, according to a study in Clinical Infectious Diseases.
Blocking the spread of HIV or favouring the spread of the tuberculosis bacteria, the flip side of the Siglec-1 protein's absence (post)
In 2016, the Retrovirology and Clinical Studies group at IrsiCaixa discovered how the absence of the Siglec-1 protein, involved in modulating the immune system, blocks the spread of HIV throughout the body. Now, a study led by the same research group and the Experimental Tuberculosis Unit of the Germans Trias i Pujol Research Institute (IGTP) has shown that, on the other hand, this same deficiency favours the dissemination of Mycobacterium tuberculosis (Mtb), the tuberculosis-causing agent. Thus, the absence of this protein helps to understand its role in different infectious contexts, and to shed light on its function in infected individuals. The study has also counted with the participation of the IVECAT research group, led by Francesc Borràs at the IGTP, as well as with the participation of more than 10 international research groups.
TB testing gap among people living with HIV is narrowing (post)
The risk of developing tuberculosis among the 38 million people living with HIV in 2019 was 18 times higher than in the rest of the world’s population. Tuberculosis remains the single largest cause of premature death among people living with HIV.
The rise of multidrug-resistant TB in HIV patients (post)
Multidrug-resistant tuberculosis (MDR-TB) was declared a public health crisis by the World Health Organization (WHO) in 2013 and each year continues to pose a serious threat to millions, especially to those infected with HIV. TB is one of the top 10 causes of death worldwide, and 15% of HIV-associated tuberculosis (TB) deaths were caused by MDR-TB in 2018. Furthermore, HIV patients are 20 times more likely to develop active TB than those without HIV.
4-month TB regimen noninferior to 6-month regimen in people with HIV (post)
A 4-month daily regimen of rifapentine and moxifloxacin was noninferior to the standard 6-month regimen for tuberculosis treatment among people with HIV enrolled in a phase 3 clinical trial, researchers reported at CROI.
HIV treatment helps prevent active TB (post)
Antiretroviral treatment (ART) reduces the risk of developing active tuberculosis (TB) in people also infected with HIV-1, by dampening the activation of the body’s immune response. These findings could help improve treatment for both conditions in the future.
CROI 2021: TB-related coverage (post)
2021 Conference on Retroviruses and Opportunistic Infections (CROI) was held virtually on 6-10 March 2021.
Building resilience needs to be central to treating drug-resistant TB (post)
A study published in The Lancet Global Health described distinct stages through drug-resistant TB (DR-TB) diagnosis and treatment from the point of view of patients with DR-TB and HIV in KwaZulu-Natal province, South Africa. The study emphasised that despite improvements in treatment, including shorter, all-oral regimens that include bedaquiline, DR-TB treatment remains lengthy, difficult, and life-changing for individuals.
Huge gaps in TB care for people living with HIV in some countries (post)
All (100%) of people living with HIV newly started on antiretroviral therapy should receive either tuberculosis (TB) preventive treatment (blue bar) or TB treatment (orange bar)—together, they represent “optimal TB care”. The green bar shows the percentage of people newly started on antiretroviral therapy who did not receive optimal TB care and are vulnerable to falling ill or dying from TB.
Page 36 of 52 · Total posts: 0
←First 35 36 37 Last→